In the context of glaucoma therapy, the CasRx system predominantly focuses on the RNA‐level knockdown of aquaporin 1 (Aqp1), β2‐adrenergic receptor (Adrb2), and Rho‐associated kinase 1/2 (Rock1/Rock2). Here, ADRB2 is linked to glaucoma.